34 related articles for article (PubMed ID: 26189252)
1. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Rose PG; Java JJ; Morgan MA; Alvarez-Secord A; Kesterson JP; Stehman FB; Warshal DP; Creasman WT; Hanjani P; Morris RT; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):511-515. PubMed ID: 27692669
[TBL] [Abstract][Full Text] [Related]
2. Relevance of enlarged cardiophrenic lymph nodes in determining prognosis of patients with advanced ovarian cancer.
Nuruzzaman HSM; Tan GHC; Nadarajah R; Teo M
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29331996
[TBL] [Abstract][Full Text] [Related]
3. Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer.
Chen Y; Sun Z; Cai S; Hu Y; Jiang R; Xiang L; Zang R
J Gynecol Oncol; 2024 May; 35(3):e25. PubMed ID: 38130134
[TBL] [Abstract][Full Text] [Related]
4. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
5. ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study.
Wagner P; Levine EA; Kim AC; Shen P; Fleming ND; Westin SN; Berry LK; Karakousis GC; Tanyi JL; Olson MT; Madajewski B; Ostrander B; Krishnan K; Balch CM; Bartlett DL
Ann Surg Oncol; 2024 Jul; 31(7):4743-4744. PubMed ID: 38722420
[No Abstract] [Full Text] [Related]
6. A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study.
Sindiani A; Obeidat B; Hamadeh L; Alghazo S; Al-Mohtaseb A; Alshdaifat E
Ann Med Surg (Lond); 2020 Nov; 59():254-257. PubMed ID: 33101665
[TBL] [Abstract][Full Text] [Related]
7. Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer.
Schwich E; Rebmann V; Horn PA; Celik AA; Bade-Döding C; Kimmig R; Kasimir-Bauer S; Buderath P
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382533
[TBL] [Abstract][Full Text] [Related]
8. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
9. Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013.
Prat J
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):858-69. PubMed ID: 25890882
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
Grabowskil JP; Mardas M; Markowska A; Markowska J
Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
[TBL] [Abstract][Full Text] [Related]
11. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
[TBL] [Abstract][Full Text] [Related]
12. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic staging for apparent stage I epithelial ovarian cancer.
Melamed A; Keating NL; Clemmer JT; Bregar AJ; Wright JD; Boruta DM; Schorge JO; Del Carmen MG; Rauh-Hain JA
Am J Obstet Gynecol; 2017 Jan; 216(1):50.e1-50.e12. PubMed ID: 27567562
[TBL] [Abstract][Full Text] [Related]
14. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
15. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
